Clinical trial NCT04794504 - References

Pain, Postoperative — Investigating Temporalis and Masseter Botox Injection Before Orthognathic Surgery to Improve Postoperative Pain

Citation(s)

•   Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group
  OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010 Jun;50(6):921-36. doi: 10.1111/j.1526-4610.2010.01678.x. Epub 2010 May 7.
•   Dressler D, Saberi FA, Kollewe K, Schrader C
  Safety aspects of incobotulinumtoxinA high-dose therapy. J Neural Transm (Vienna). 2015 Feb;122(2):327-33. doi: 10.1007/s00702-014-1252-9. Epub 2014 Jul 17.
•   Khalifeh M, Mehta K, Varguise N, Suarez-Durall P, Enciso R
  Botulinum toxin type A for the treatment of head and neck chronic myofascial pain syndrome: A systematic review and meta-analysis. J Am Dent Assoc. 2016 Dec;147(12):959-973.e1. doi: 10.1016/j.adaj.2016.08.022. Epub 2016 Oct 10. Review.
•   Kwon KH, Shin KS, Yeon SH, Kwon DG
  Application of botulinum toxin in maxillofacial field: part I. Bruxism and square jaw. Maxillofac Plast Reconstr Surg. 2019 Oct 1;41(1):38. doi: 10.1186/s40902-019-0218-0. eCollection 2019 Dec. Review.
•   Machado D, Martimbianco ALC, Bussadori SK, Pacheco RL, Riera R, Santos EM
  Botulinum Toxin Type A for Painful Temporomandibular Disorders: Systematic Review and Meta-Analysis. J Pain. 2020 Mar - Apr;21(3-4):281-293. doi: 10.1016/j.jpain.2019.08.011. Epub 2019 Sep 9. Review.
•   Mimeh H, Fenech Magrin AM, Myers S, Ghanem AM
  A Critical Review of Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Migraine in Adults. Aesthet Surg J. 2019 Jul 12;39(8):898-907. doi: 10.1093/asj/sjy224. Review.
•   Naran S, Steinbacher DM, Taylor JA
  Current Concepts in Orthognathic Surgery. Plast Reconstr Surg. 2018 Jun;141(6):925e-936e. doi: 10.1097/PRS.0000000000004438. Review.
•   Patel AA, Lerner MZ, Blitzer A
  IncobotulinumtoxinA Injection for Temporomandibular Joint Disorder. Ann Otol Rhinol Laryngol. 2017 Apr;126(4):328-333. doi: 10.1177/0003489417693013. Epub 2017 Feb 1.
•   Phillips C, Blakey G 3rd, Jaskolka M
  Recovery after orthognathic surgery: short-term health-related quality of life outcomes. J Oral Maxillofac Surg. 2008 Oct;66(10):2110-5. doi: 10.1016/j.joms.2008.06.080.
•   Raschke GF, Meissner W, Peisker A, Djedovic G, Rieger U, Guentsch A, Dammeier MG, Schultze-Mosgau S
  Bilateral sagittal split osteotomy-parameters and correlations of postoperative pain management. Clin Oral Investig. 2018 Jan;22(1):181-187. doi: 10.1007/s00784-017-2097-z. Epub 2017 Mar 14.
•   Scaglione F
  Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice. Toxins (Basel). 2016 Mar 4;8(3). pii: E65. doi: 10.3390/toxins8030065. Review.
•   Walker TJ, Dayan SH
  Comparison and overview of currently available neurotoxins. J Clin Aesthet Dermatol. 2014 Feb;7(2):31-9. Review.
•   Yeh YT, Peng JH, Peng HP
  Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy. J Cosmet Dermatol. 2018 Oct;17(5):675-687. doi: 10.1111/jocd.12721. Epub 2018 Aug 9. Review.

Botulinum Toxin Type A Injected Into the Temporalis and Masseter Before Orthognathic Surgery to Improve Postoperative Pain

Details for clinical trial NCT04794504